Cryoport Reports First Quarter 2026 Financial Results
Cryoport reported Q1 2026 revenue of $47.8 million, up 16% year-over-year, driven by 26% growth in commercial cell and gene therapy revenue and broad-based strength across its services and products segments. Management raised full-year revenue guidance to $192 million to $196 million, citing increased visibility and a strong start to the year, while adjusted EBITDA improved by $2.2 million.
Key figures
- Revenue
- 47800000
- Guidance
- full-year revenue guidance to $192 million - $196 million
- Revenue Yoy
- 16%
- Cash position
- $403.6 million
- Commercial cgt revenue
- $9.1 million
- Clinical trials supported
- 766
- Commercial cgts supported
- 21
- Commercial cgt revenue yoy
- 26%
- Adjusted ebitda improvement
- $2.2 million
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.